(WASHINGTON) – An FDA panel has recommended approval of the investigative weight-loss drug Contrave, even after two such drugs up for approval in 2010 were rejected.
The panel voted 13-to-7 to give Contrave the green light, despite blood pressure risks associated with the drug.
The FDA has until January to decide whether to approve the drug. Two other weight-loss medications, Qnexa and Lorqess, were rejected this year.
Contrave was said to have the least side effects of the three new agents, but also appeared to be the least effective in terms of weight loss.
Copyright 2010 ABC News Radio